211 related articles for article (PubMed ID: 32593915)
21. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
22. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
23. Ischemic stroke during cisplatin-based chemotherapy for testicular germ cell tumor: case report and review of the literature.
Meattini I; Scotti V; Pescini F; Livi L; Sulprizio S; Palumbo V; Sarti C; Biti G
J Chemother; 2010 Apr; 22(2):134-6. PubMed ID: 20435575
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin and etoposide for metastatic testis cancer in a renal transplant recipient.
Vogelzang NJ
J Urol; 1990 Jun; 143(6):1235-6. PubMed ID: 2160550
[TBL] [Abstract][Full Text] [Related]
25. Reassessment of 4-Cycle Etoposide and Cisplatin as the Standard of Care for Good-Risk Metastatic Germ Cell Tumors.
Fein DE; Paulus JK; Mathew P
JAMA Oncol; 2018 Dec; 4(12):1661-1662. PubMed ID: 30325997
[No Abstract] [Full Text] [Related]
26. Ifosfamide in testicular cancer: the Indiana University experience.
Loehrer PJ; Williams SD; Einhorn LH
Semin Oncol; 1989 Feb; 16(1 Suppl 3):96-101. PubMed ID: 2539649
[TBL] [Abstract][Full Text] [Related]
27. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
Oing C; Lorch A
Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
[TBL] [Abstract][Full Text] [Related]
28. [Cisplatin in the treatment of testicular carcinoma].
van Groeningen CJ; Pinedo HM
Ned Tijdschr Geneeskd; 1986 Nov; 130(44):1980-4. PubMed ID: 3022163
[No Abstract] [Full Text] [Related]
29. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
[TBL] [Abstract][Full Text] [Related]
30. [VP-16 salvage therapy of PVB regimen-resistant testicular germ cell tumors].
Yamazaki H; Yuichiro A; Kondo N; Imanaka K; Machida T
Nihon Hinyokika Gakkai Zasshi; 1987 Jul; 78(7):1227-31. PubMed ID: 2446041
[No Abstract] [Full Text] [Related]
31. [Late toxicity after chemotherapy of malignant testicular tumors].
Jakob A; Kollmannsberger C; Kanz L; Bokemeyer C
Urologe A; 1998 Nov; 37(6):635-47. PubMed ID: 9887493
[TBL] [Abstract][Full Text] [Related]
32. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer.
Kawai K; Akaza H
Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501
[TBL] [Abstract][Full Text] [Related]
33. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy of disseminated germ cell tumors.
Einhorn LH
Cancer; 1987 Aug; 60(3 Suppl):570-3. PubMed ID: 2439185
[TBL] [Abstract][Full Text] [Related]
35. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
36. Understanding the crosstalk of molecular factors and signaling pathways reveals novel biomarkers of cisplatin resistance in testicular germ cell tumors.
Roska J; Jurkovicova D
Neoplasma; 2020 Jan; 67(1):1-14. PubMed ID: 31829026
[TBL] [Abstract][Full Text] [Related]
37. The role of ifosfamide in the treatment of nonseminomatous testicular cancer.
Scheulen ME; Niederle N; Kath R; Wandl UB; Seeber S; Schmidt CG
Prog Clin Biol Res; 1988; 269():439-50. PubMed ID: 2455912
[No Abstract] [Full Text] [Related]
38. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
40. Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W; Seidel C; Bokemeyer C; Oing C
Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
